E

arly last year, a former Valeant Pharmaceuticals (VRX) executive told Congress that, when the company took huge price hikes on two life-saving heart drugs in 2013, the drug maker believed the move “should not reduce patient access.”

He was wrong.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine